Able Laboratories

Able has a talented and dedicated group of pharmacists, chemists and scientists working on the development of a broad range of generic products. At any given time, our team is working on multiple new formulations utilizing our fully equipped and extensive scientific laboratory. The Company's R & D strategy is to focus on: Generic drugs that have la... rge, established markets; Niche products with limited or no competition; Challenging products that require expertise such as suppositories and extended release formulations and Developing liquid formulations Our research and development activities consist of: Identifying brand-name drugs for which patent protection has expired or will expire in the near future; Conducting research and developing new product formulations based upon such drugs; Developing and testing our formulations as necessary; Compiling and submitting the information to the FDA; and Obtaining approval from the FDA for our new product formulations. As of February 15, 2005, we had six Abbreviated New Drug Applications pending approval at the FDA. Our product development program includes multiple active projects in various stages of completion. For the year ended December 31, 2004, we spent $15.2 million on research and development activities, compared with $11.2 million for the year ended December 31, 2003 and $6.9 million for the year ended December 31, 2002. Our R & D team's efforts produced 16 Abbreviated New Drug Application approvals during 2004. As of December 31, 2004 we had 30 FDA approved product families in 70 different product strengths available for sale. The continuing efforts of our R&D team are a cornerstone of Able's growth and its future.Read More